About Lucid Genomics
The health tech start-up Lucid Genomics has developed an AI-based digital health tech platform for comprehensive DNA analysis in order to detect genetic diseases faster and more precisely. The start-up wants to ensure that users in the healthcare and pharmaceutical sectors can extract all genomic information - including that from the "dark genome", which cannot be comprehensively read using previous approaches - from DNA for more precise diagnostics and advanced drug development. Lucid Genomics is a spin-off of the Max Planck Institute for Molecular Genetics and Charité - Universitätsmedizin Berlin. The company was founded by Uirá Souto Melo (CEO) and Hossein Moeinzadeh (CTO) and is based on the cutting-edge research of Prof. Dr. Stefan Mundlos and Prof. Dr. Martin Vingron.
Note: This article has been translated using a computer system without human intervention. LUMITOS offers these automatic translations to present a wider range of company presentation. Since this article has been translated with automatic translation, it is possible that it contains errors in vocabulary, syntax or grammar. The original article in German can be found here.
- Founding: 2024
- Focus : Manufacturer
- Employees: 1-10
- Industry : Diagnostics, IT
